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The Effects of Potassium Channel Openers on Saphenous Vein Exposed 
to Arterial Flow • 
D. K. Beattiet, M. Gosling, A. H. Davies and J. T. Powelll- 
Departments of Surgery, Charing Cross & Westminster Medical School, St Dunstan;s Road, London W6 8RP 
Objectives: To assess the sensitivity of saphenous vein to potassium channel opening drugs (KCOs). 
Methods: Saphenous vein, harvested at bypass urgery or high Iigation for correction of varicose veins, was exposed to 
an in vitro flow circuit and vasomotor responses a sessed by organ bath pharmacology. 
Outcome measures" Effective drug concentrations for 50% reduction in vein ring tension (ICso). 
Results: Vein rings pre-contracted with phenylephrine showed aconcentration-dependent relaxation to all the KCOs tested 
with a potency ranking of HOE 234>cromakalim>pinacidil>diazoxide. The relaxation to cromakalim was endothelium- 
independent and was inhibited by glibenclamide (an ATP-sensitive K+ channel blocker). The sensitivity of vein rings to 
cromakalim increased after exposure to arterial flow conditions for 90 minutes (IC5o before 1.7+_0.25pM and after 
0.25+ 0.08 #M, p >0.001). This effect was not evident after 90 min of venous flow conditions, 2.19 + 0.49 #M. When 
the workload on vein, exposed to arterial flow conditions, was reduced mechanically b  external stenting with PTFE the 
increased sensitivity to cromakalim was abolished. 
Conclusion: Saphenous vein has A TP-sensitive K + channels responsive toKCOs. The increased sensitivity to cromakalim, 
induced by arterial flow conditions, may represent an endogenous protective mechanism limiting ischaemic damage 
resulting from the higher workload imposed on grafted vein. 
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Introduction 
Human saphenous vein remains the most widely used 
conduit in peripheral arterial reconstruction. Never- 
theless up to 30% of grafts fail, usually within 1 year. 1
Trauma, hypoxia and the exposure of the vein to the 
haemodynamics of arterial flow are all thought o 
contribute to the tissue remodelling which occurs. 2
The structural changes in the vein include the de- 
velopment of intimal hyperplasia secondary to smooth 
muscle cell replication and migration. 3 Functional 
changes include increased catecholamine s nsitivity 4'5
and alterations in endothelium-dependent vaso- 
relaxation. 6 The increased workload to which the vein 
is subjected in the arterial circulation probably is 
pivotal to the adaptive response and related structural 
and functional changes. 
Potassium channel opening drugs (KCOs) are a 
relatively new class of drug whose vasorelaxant prop- 
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erties already are being exploited to reduce workload 
in angina, hypertension and in peripheral vascular 
disease. 7-1° The mechanism of action of KCOs is at- 
tributed to activation of ATP-dependent potassium 
(KATP) channels. KAT p channels were first described in 
smooth muscle in 1989.1~ Their function is related to 
intracellular ATP concentration; reduction of ATP as 
a result of metabolic stress leads to KAT P channel ac- 
tivation, reduced cell excitability, and hence a re- 
duction in workload. The KAT P channel is regulated 
directly by the concentrations of intracellular ATP. As 
ATP falls, KAT P channels become active, resulting in 
K ÷ efflux from cells and cellular hyperpolarization. 
These changes oppose the opening of Ca2+-permeable 
channels and promote vasorelaxation. Thus KAT P chan- 
nels represent an elegant physiological mechanism 
through which the contractile ability of a muscle cell 
is directly coupled to its metabolic status. The presence 
of KAT P channels in saphenous vein has been suggested, 
since the potassium channel opener levcromakalim 
relaxes precontracted vein. ~2 The suggested clinical 
uses of KCOs include ischaemic pre-conditioning. ~3 In 
this study we have investigated the hypothesis that 
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saphenous vein smooth muscle cells have KAT P chan- 
nels, which could be manipulated pharmacologically 
with KCOs to provide ischaemic pre-conditioning of 
venous bypass grafts. 
Material and Methods 
Vein harvesting and perfusion 
Segments of human saphenous vein were taken from 
non-diabetic patients undergoing bypass urgery, both 
peripheral and cardiac, amputation and high ligation 
for correction of varicose veins. The use of saphenous 
vein, for the investigations reported here, was ap- 
proved by the local Ethical Committee. Veins were 
transported immediately to the laboratory in fresh, 
cooled pre-oxygenated Kreb's solution (4 °C, 95% O2, 
5% CO2). Utilised vein was non-distended and had 
not been perfused. All loose connective tissue was 
removed from the vein and a ring of vein taken as 
a control. A further segment of vein was removed, 
immediately snap-frozen i  liquid nitrogen, and stored 
at -70  °C for later ATP analysis. The tissue was 
weighed before being pulverised in liquid nitrogen 
and extracted into 0.9 M perchloric acid. ATP was 
quantified by an enzymatic method. 14 
The remaining segment of vein was mounted on a 
retaining jig and placed into an in vitro circuit as 
described previously. 15Briefly, this consisted of a litre 
perfusate reservoir connected to the retaining jig via a 
cardiac bypass pump (Stockert Instrumente, Munich), 
thus allowing variations in flow rate, pressure and 
frequency to be made. Vein segments were perfused 
with warmed, oxygenated Kreb's solution (37 °C, 95% 
02, 5% CO2) and the retaining jig was immersed in a 
similar solution to externally bathe the vein. Modified 
Kreb's solution (NaC1 118.4, KC1 4.7mmol, KHRPO4 
1.2 mmol, MgSO4.7H20 1.2 mmol, glucose 11.1 mmol, 
NaHCO324.9 mmol, CaC122.5 mmol) was made freshly 
each day. Flow rate was measured at the beginning 
and end of each period of perfusion and the perfusion 
was continually monitored. Perfusate temperature was 
measured at two points in the circuit. The diameters 
of the vein wall during perfusion was recorded using 
a combination Of B and M mode ultrasound (Aloka 
SSD500) with 7.5 MHz linear transducer. 
Vein segments were perfused under the following 
conditons: 
Arterial flow, in a pulsatile manner at 90 cycles per 
minute, with a mean pressure of 100 mmHg and flow 
rate of 200 ml/min for 90 min. 
Venous flow, in a non-pulsatile manner with a pressure 
of 20 mmHg and a flow rate of 10 ml/min for 90 min. 
Organ Bath Experiments 
Vein rings were mounted on 0.2 mm stainless steel 
stirrups placed through the lumen in organ baths of 
10 ml internal capacity. One stirrup was fixed whilst 
the other was connected to an isometric force 
transducer (Harvard Apparatus, Massachusetts) and 
changes in tension generated by the rings recorded in 
both electronic (MacLab Software ®) format and on 
hard copy (Student Oscillograph, Harvard Apparatus, 
Kent). The organ bath was filled with warmed oxy- 
genated Kreb's solution (37 °C, 95% O2, 5% CO2). Vein 
rings were initially placed under 2 g of tension and 
allowed to relax to equilibrium. 
Vein rings were contracted with potassium chloride 
(40 mM), washed out and recontracted, submaximally, 
with phenylephrine. The relaxation of vein rings in 
response to increasing concentrations of the potassium 
channel openers cromakalim (Sigma, UK), HOE 234 
(a gift from Hoechst, Germany), pinacidil and diazo- 
xide. For some experiments vein rings were pre-in- 
cubated with glibenclamide (Sigma, UK). The presence 
of functional endothelium on vein rings was assessed 
from relaxation of pre-contracted vein rings to the 
calcium ionophore, A23187. Vein rings were denuded 
of endothelium by passing a wire across the lumenal 
surface. Stock solutions of diazoxide, pinacidil and 
HOE 234 were made up in DMSO (Sigma, UK) whilst 
cr0makalim and glibenclamide were dissolved in eth- 
anol (British Drug Houses, UK). Vehicle controls using 
the maximum concentration of these solvents caused 
no relaxation of vein rings precontracted with phenyl- 
ephrine. 
Analysis of Data 
Differences in ATP concentrations were compared by 
Student's paired t-test. Relaxation of vein rings was 
reported as a percentage of the contraction to phenyl- 
ephrine (mean+s.~.M.). The 50% effective con- 
centrations (ECs0) for phenylephrine were calculated 
by normalising data to the peak response and fitting 
the concentration-response curves to a logistic plot 
incorporating Hill coefficient using MicroCal Origin 
(MicroCal Inc., Northampton, MA, USA). The con- 
centrations of potassium channel openers causing 50% 
inhibition of contraction (IC50) were calculated in a 
similar manner. Evaluation of this data was performed 
using the Student's t-test for paired-observations or 
for concentration-response curves using repeated 
measures analysis of variance, followed by Bonferroni 
multiple comparison test (Statview 4.0 for Macintosh). 
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Fig. 1. (a) Oscillograph tracing to show the maintained contraction of a freshly excised saphenous vein ring precontracted with 
phenylephrine up to 0.1 mM. (b) Oscillograph tracing to show the relaxation of a freshly excised saphenous vein ring, precontracted with 
phenylephrine (0.1 mM), to increasing concentrations of cromakalim. 
Results 
Functional, non-diseased vein supported a contraction 
of >2g (mean 4.4+0.7g) in response to increasing 
concentrations of phenylephrine, ECs0 10.9+2.0~tM. 
The ATP content of this freshly excised vein was 
385 + 81 nmol /g  tissue wet weight. After vein has been 
exposed to either venous or arterial flow conditions for 
90 minutes in the in vitro circuit, the ATP concentration 
remained unchanged. After venous circuits the EC50 
for phenylephrine (9.2 + 1.2 ~tM) was unchanged, but 
after arterial circuits the ECs0 for phenylephrine had 
decreased to 2.1_+ 0.5 pM, p <0.001 compared with 
freshly excised vein. 
After vein rings had been submaximal ly contracted 
with phenylephrine, increasing concentrations of 
potassium channel openers (KCOs) effected increasing 
vasorelaxation. The response to cromakal im is shown 
in Figure 1. The concentration-dependence of this 
relaxation was similar in veins with endothel ium and 
vein rings denuded of endothel ium (Figure 2). The 
concentration of cromakal im which caused 50% re- 
laxation (ICs0) was 1.7 + 0.25 ~tM. Pre-incubation of the 
vein ring with 30 ~tM glibenclamide (a KAT p channel 
blocker) abolished the relaxation in response to cro- 
makal im (Figure 2). 
The potency of four different KCOs in causing re- 
laxation of pre-contracted vein rings was compared. 
The most potent drug was HOE 234 (IC50 0.2 + 0.04 ~tM), 
followed by cromakal im (ICs0 1.7±0.25pM), and 
pinacidil (ICs0 5.8 + 0.7 pM), with diazoxide being the 
least potent (ICs0 36 + 4.4 ~tM), see Table 1. Cromakal im 
was used for all further experiments. 
When vein is exposed to arterial flow conditions in 
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Fig. 2. The response to cromakalim is endothelium-independent 
and blocked by glibenclamide. The relaxation of pre-contracted vein 
rings, with endothelium (O) or denuded of endothelium (.), in 
response to increasing concentrations of cromakalim. The relaxation 
was abolished when vein rings were pre-incubated with 100 pM 
glibenclamide (A). 
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Table 1. The sens i t iv i ty  o f  human saphenous  ve in  to the  vasore laxant  effect of potass ium channe l  
open ing  drugs .  
Diazoxide Pinacidil Cromakalim HOE234 
ICs0 for freshly isolated 38 + 1.3 3.16 ± 1.25 1.7 + 0.25 0.043 -t- 0.012 
vein ~tM (S.E.M.) 
ICs0 for vein after 90 min n.d. 1.70+_0.77 0.25+0.08* n.d. 
of arterial flow pM (S.~.M.) 
n.d. = not determined. 
* Significant reduction compared to freshly excised vein, p <0.0001. 
Fig. 3. Pulsatile circumferential distension ofvein exposed to arterial 
flow is limited by external stenting. The B mode image is shown 
on the left-hand side of each picture. On the right the M-mode trace 
follows wall motion through three simulated arterial pulse cycles: 
(a) the large change in diameter of unstented vein (arrow); 
(b) the limited change in diameter of stented vein (arrow). 
vein, with peak venous  d iameter  increasing by -35% 
with each cycle. 16 This change in d iameter  can be 
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Fig. 4. The heightened sensivity to cromakalim of vein exposed 
to arterial flow conditions is abolished by external stenting. The 
relaxation of pre-contracted vein rings to cromakalim after exposure 
to venous flow conditions for 90 min (@) or arterial flow conditions 
for 90 rain (V). These latter vein rings relax at much lower con- 
centrations ofcromakalim. The interrupted line shows the response 
of stented veins exposed to arterial flow for 90 rain; the sensitivity 
to cromakalim has not increased. 
This cyclical c ircumferential  deformat ion can be l im- 
ited by  plac ing the ve in  in an external PTFE stent 
(Figure 3b). This l imitat ion of external stent ing is l ikely 
to decrease mechanica l ly  the work load on the ve in  
exposed to arterial flow. 
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Fig. 5. Hypothesis for mechanism of vein graft protection by potas- 
sium channel openers (KCOs). 
After vein had been exposed to arterial (but not 
venous) flow conditions for 90 rain the IC50 for cro- 
makalim decreased significantly from 1.7 + 0.25 IXM to 
0.25 + 0.08 laM, p <0.001 (Figure 4). After venous flow 
conditions for 90 min the ICs0 for cromakalim was 
2.19+0.49gM. This increased sensitivity of vein to 
cromakalim was observed only in unstented vein: the 
ICs0 for cromakalim (1.02+0.19~M) remained un- 
changed in stented vein (Figure 4). 
Since external stenting of vein exposed to arterial 
flow for 90 min abolished the increased sensitivity of 
vein rings to both phenylephrine 16 and cromakalim, 
these changes appear to be a response to increased 
workload. Therefore, we considered whether pre-con- 
ditioning vein by inclusion of cromakalim in the vein 
perfusate could decrease the workload pharmaco- 
logically and abolish the increased sensitivity of ar- 
terial-perfused vein rings to phenylephrine. When 
5 gM cromakalim was included in the Kreb's solution 
perfusing veins exposed to arterial flow for 90 min the 
contractile response to phenylephrine was normalised, 
the ECs0 increasing from 2.1 __+ 0.5 gM in the absence of 
drug to 7.0 + 2.2 gM in the presence of cromakalim. 
Discussion 
Here we report that human saphenous vein smooth 
muscle cells possess ATP-sensitive K + channels which 
are sensitive to potassium channel opening drugs. 
Potassium channel openers are finding increasing clin- 
ical usage for cardiovascular disease, particularly in the 
area of ischaemic pre-conditioning. 13 When saphenous 
vein is used as an arterial bypass conduit he workload 
increases as a result of the pulsatile arterial flow and 
the increased sensitivity of the newly implanted vein 
bypass to circulating catecholamines acts in synergy 
to increase the graft workload. 14A6'17 This combination 
is predicted to promote muscle hypoxia and decrease 
intracellular ATP/ADP ratio (Figure 5). Such muscle 
hypoxia has been suggested to promote the de- 
velopment of intimal hyperplasia. TM The relaxant and 
metabolic effects of potassium channel openers could 
be used to avert these unwanted effects: this is termed 
clinically as ischaemic preconditioning. 
The potassium channel openers currently approved 
for clinical use in Britain include nicorandil, diazoxide 
and minoxidil. Other drugs, including pinacidil, are 
approved in Europe and many more are under de- 
velopment. The drugs used in this study belong to 
three different structural classes: benzopyrans (e.g. 
cromakalim, HOE 234), cyanoguanidines (pinacidil) 
and benzothiadiazones (diazoxide), and we have 
shown that, for saphenous vein, the benzopyrans are 
the most potent of the potassium channel openers. 
The effect of benzopyrans to relax pre-contracted vein 
rings was independent ofthe presence of endothelium 
but could be inhibited by the oral hypoglycaemic drug 
glibenclamide. 
To enable investigation of the adaptation of sa- 
phenous vein to arterial flow, we have developed and 
validated an in vitro flow circuit. 15 After exposure of 
saphenous vein to arterial flow conditions for 90 min 
the sensitivity of vein rings to cromakalim was in- 
creased significantly, the ICs0 decreasing from 1.7 gM 
in freshly excised vein to 0.25 gM after arterial flow. 
In contrast, the sensitivity of veins to the less potent 
KCO, pinacidil remained unchanged. The increased 
sensitivity to cromakalim was not observed when 
veins were exposed to venous flow in vitro. These data 
imply that ATP-sensitive potassium channels par- 
ticipate in the adaptive responses of newly implanted 
saphenous vein grafts. 
External stenting of saphenous vein with PTFE 
attenuates the workload on new vein grafts. Experi- 
mentally the external stenting of porcine interposition 
vein grafts has been demonstrated to reduce intimal 
thickening and maintain lumen diameter. 19Interest- 
ingly, snug-fit or over-sizing of the external porous 
stent did not alter these beneficial effects. External 
stenting also has been shown to attenuate some of the 
endothelial changes which occur when saphenous vein 
is exposed to arterial flow. 16 Following these results 
some cardiac surgeons have initiated a clinical trial of 
external stenting of both aortocoronary and femoro- 
distal vein grafts. Our results indicate that KCO ther- 
apy could provide an alternative approach to reduce 
the workload on newly inplanted vein grafts. 
In our in vitro studies, external stenting of the sa- 
phenous vein abolished the arterial flow-induced in- 
crease in sensitivity to cromakalim observed in 
unstented vein. The ultrasonographic studies confirm 
that the circumferential distension of saphenous vein 
Eur J Vasc Endovasc Surg Vol 15, March 1998 
The Effects of KCOs on Saphenous Vein Exposed to Arterial Flow 249 
is limited by external stenting (Figure 3). 16 In the 
presence of constant flow, if circumferential de- 
formation is limited shear stress increases: in 
saphenous vein exposed to arterial flow this could 
increase the shear stress in externally stented veins by 
50%. This increase in shear stress may have separate 
effects, transduced by the endothelium, on the under- 
lying smooth muscle. Therefore, the increased sensi- 
tivity to cromakalim, commented on above, which is 
endothelium-independent and abolished in externally 
stented vein, is a consequence of circumferential de- 
formation and not increased shear stress. 
The practice of ischaemic pre-conditioning may be 
a novel approach for the vascular surgeon. There are 
reports that potassium channel openers are in clinical 
trial for the treatment of intermittent claudication. 13
We are reluctant to pursue our studies in experimental 
models, since although many drugs have proved 
effective in limiting intimal hyperplasia in animal 
models none have been effective in man. Therefore, 
our current approach is to extend our in vitro studies 
before suggesting appropriate drugs for clinical evalu- 
ation. 
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